Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
about
Interventions for guttate psoriasisSystemic pharmacological treatments for chronic plaque psoriasisHidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatmentsReview of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasisUstekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvementEfficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment.Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece.Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab.Ustekinumab: differential use in psoriasisComparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled studyUstekinumab in the Treatment of Psoriasis and Psoriatic Arthritis.Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.Ustekinumab for the treatment of psoriasis.Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland.Topical psoriasis therapy in the age of biologics: evidence-based treatment recommendations.Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.Cost effectiveness of biologic therapies for plaque psoriasis.Biological therapies for psoriasis.Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials.Fatigue in psoriasis: a phenomenon to be explored.Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service.A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis.Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis.Comparative effectiveness of biologic therapies on improvements in quality of life in patients with psoriasis.Fatigue - an underestimated symptom in psoriatic arthritisEffect of Oral PUVAsol on the Quality of Life in Indian Patients Having Chronic Plaque Psoriasis.Fumaderm® in daily practice for psoriasis: dosing, efficacy and quality of life.Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.Patient preferences for psoriasis treatments: impact of treatment experience.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary.
P2860
Q24188296-6BB9AAEF-808A-44C7-92B8-B855EF74C4C4Q24188334-F5B08961-186E-41E3-A5AC-32E4D72D677FQ27022866-7AFF5966-0712-47E0-870A-CFEA3FDEBFD6Q28280687-32214C36-6D94-437C-8ACA-344C23285092Q30620977-86A56347-D2C5-47D5-BEB3-8085EAF20F13Q34190076-84A45C01-3AF9-4420-943B-D06BC10B389BQ34351604-5DEA2EC0-4532-4A41-B306-338DB5F95825Q34502118-1F400C6E-AE54-41B2-99CB-6AF4124F56ACQ35096980-58C36C28-5117-4085-A9B8-91B154D0C336Q36033361-0A9DAEE5-3915-4D2C-A2B5-58B4B4C50FA1Q36866954-731041C6-92B1-4FAD-958F-B63DEF772779Q36942960-901A21DB-992B-4074-8A63-9CF45BFD7BF5Q37631750-90C7378A-84CC-4C21-87B6-5612832DF5F0Q37717828-1278DD63-429D-4349-83BD-21D6051981B8Q37846678-8050575B-61FC-4CBC-9736-7B665270788DQ37855945-270855B4-CA16-43AF-9844-BC4B52AB26ABQ37857328-FB090F68-A463-429B-9A3E-46F55C163246Q37898704-037CD038-45B5-48F0-863A-8448A62D40B8Q37929165-293E819B-1180-4D39-89DB-DB549839F1D1Q37935050-6F4A4A77-FDF3-41DC-8721-DD91E2BA567CQ37971835-E69A463D-A429-4E45-831A-EF10D3BC841BQ38083089-9A41110D-883D-4E25-AD6B-92F3858E0D01Q38098466-DDE408F7-0A14-4850-923A-5E5871C6D777Q38108567-F4B9E2A7-DACC-4C20-A89B-88806828BF7CQ38155648-9168EF14-7B66-4838-80A5-B0D61DFF82E5Q38205035-D786AF9A-5449-4560-9261-1EB3BCDB94D6Q38268725-EAC14714-78FF-459D-96C3-C54EE4548D44Q38306698-0EDCFEF1-A56B-477E-9BBD-4F8AD10A96C8Q38636664-AF76C431-AB80-48AF-9520-C3073BF49F25Q38858335-9D8C79BA-3071-427B-ACA1-85CCD0452794Q39498625-AAB615AA-9A81-4E1E-8C16-DE34B92F2991Q40261663-92624BC9-6B99-4B51-83E2-682900275860Q41170483-A7CD24E8-0C7C-4AAD-A535-F0AFB1F2229DQ41889404-9E64B497-3101-49D4-A074-E9F5AEEA748DQ43645804-CCAC497D-6A9C-4DFD-896D-45585CA4F639Q44554932-A9E2CB14-1ED7-41F9-A84E-53A21B724BCFQ44849386-9358B9C0-0763-4288-82D8-AA3F5CBFC958Q47260366-CE9D7C16-500E-4CAF-BC84-264580FFDE75Q47644680-0420866B-7BDA-4A96-9D48-C8564318D521Q47892380-B625678F-C30E-4230-A0CF-C8C8A0FDE5B4
P2860
Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Ustekinumab improves health-re ...... ults from the PHOENIX 1 trial.
@en
Ustekinumab improves health-re ...... ults from the PHOENIX 1 trial.
@nl
type
label
Ustekinumab improves health-re ...... ults from the PHOENIX 1 trial.
@en
Ustekinumab improves health-re ...... ults from the PHOENIX 1 trial.
@nl
prefLabel
Ustekinumab improves health-re ...... ults from the PHOENIX 1 trial.
@en
Ustekinumab improves health-re ...... ults from the PHOENIX 1 trial.
@nl
P2093
P1476
Ustekinumab improves health-re ...... ults from the PHOENIX 1 trial.
@en
P2093
P304
P356
10.1111/J.1365-2133.2009.09491.X
P407
P50
P577
2009-11-09T00:00:00Z